Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for its HP-3000

Shots:

• Hisamitsu to receive upfront, milestone based on the regulatory approval and royalties on sales of product. Kyowa Kirin to get exclusive commercialization rights for Hisamitsu’s HP-3000, post marketing approval in Japan
• The focus of the agreement is to develop & commercialize therapies for Parkinson’s disease developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology
• Hisamitsu’s HP-3000 is a transdermal skin patch, evaluated in P-III study for Parkinson’s disease has met 1EPs, with its NDA filled in Sept,2018 and expected approval in Feb, 2020

Click here read full press release/ article | Ref: Kyowa Kirin | Image:  Thailand Medical News